Fissurectomy and anoplasty with botulinum toxin injection in patients with chronic anal posterior fissure with hypertonia: a long-term evaluation

Beatrice D’Orazio1,2 · Girolamo Geraci1 · Guido Martorana3 · Carmelo Sciumé1 · Giovanni Corbo1,2 · Gaetano Di Vita1

Received: 13 May 2020 / Accepted: 1 July 2020 / Published online: 14 July 2020
© The Author(s) 2020

Abstract
Chronic anal fissure’s (CAF) etiopathogenesis remain unclear. CAF of the posterior commissure (CAPF) are often characterized by internal anal sphincter (IAS) hypertonia. The treatment of this disease aimed to reduce IAS hypertonia. Due to the high rate of anal incontinence after LIS, the employment of sphincter preserving surgical techniques associated to pharmacological sphincterotomy appears more sensible. The aim of our study is to evaluate the long-term results of fissurectomy and anoplasty with V–Y cutaneous flap advancement associated to 30 UI of botulinum toxin injection for CAPF with IAS hypertonia. We enrolled 45 patients undergone to fissurectomy and anoplasty with V–Y cutaneous flap advancement and 30 UI botulinum toxin injection. All patients were followed up for at least 5 years after the surgical procedure, with evaluation of anal continence, recurrence rate and MRP (Maximum resting pressure), MSP (Maximum restricting pressure), USWA (Ultrasound wave activity). All patients healed within 40 days after surgery. We observed 3 “de novo” post-operative anal incontinence cases, temporary and minor; the pre-operative ones have only temporary worsened after surgery. We reported 3 cases of recurrences, within 2 years from surgery, all healed after conservative medical therapy. At 5 year follow-up post-operative manometric findings were similar to those of healthy subjects. At 5 years after the surgical procedure, we achieved good results, and these evidences show that surgical section of the IAS is not at all necessary for the healing process of the CAPF.

Keywords
Proctology · Anal fissure · Fissurectomy · Anoplasty · Sphincterotomy · Botulinum toxin

Introduction
Chronic anal fissure (CAF) is one of the most frequent proctological disease, its clinical features are post-defecation bleeding, itching and pain, which can last from few minutes–hours. CAF most frequently occur at the posterior commissure (CAPF) [1], nevertheless, to present the etiopathogenesis of the disease remains unclear. CAPF are characterized, more often than CAF at the anterior commissure, by internal anal sphincter (IAS) hypertonia. To date, the role of this latter feature is unknown, and we still wonder whether it is a cause or a consequence of CAF disease. During the last few decades, the treatment of this disease aimed to reduce IAS hypertonia with medical or surgical techniques. Surgical lateral internal sphincterotomy (LIS) represents nowadays the gold standard treatment for CAFs, which are refractory to the pharmacological therapy; this surgical procedure is burdened by low rate of post-operative complications and high healing rate. The great disadvantage of the latter procedure is the high rate of anal incontinence, which can occur in up to 30–40% of cases. A recent meta-analysis [2] evaluating long-term incidence of anal incontinence after LIS, showed an overall continence alteration risk of 14%; however, on severity analysis, flatus incontinence
and soilage/seepage were much commoner than frank incontinence to liquid or solid stool.

Anal incontinence has a strong impact on the quality of life of patients and it can be more disabling than CAF itself [3]; as a matter of fact, patients tend to bear better the recurrence than the fecal incontinence [4].

To preserve the anatomical and functional integrity of the sphincter system as well as to reduce the anal incontinence incidence, the surgical procedures mostly used for the treatment of CAPF are fissurectomy alone or fissurectomy and pharmacological sphincterotomy, which can be associated with cutaneous and mucous flap.

The aim of our study is to evaluate the results of fissurectomy and anoplasty with V–Y cutaneous flap advancement associated to 30 UI of botulinum toxin injection, at 5 years after the sphincter-saving surgical procedure, as a treatment for CAPF with IAS hypertonia.

**Materials and methods**

We enrolled 45 patients, all affected by idiopathic and non-recurrent CAPF with hypertonic IAS, who underwent fissurectomy and anoplasty with V–Y cutaneous flap advancement and 30 UI botulinum toxin injection, from January 2011 until January 2015. All patients were followed up for at least 5 years after the surgical procedure. The patients’ outcome data were retrieved from a prospectively monitored database.

Pre-operative manometric evaluation was performed after a reasonable period of suspension of all medical therapy influencing IAS tone. The manometric evaluation was carried out by a manometric sensor (2.1 mm external diameter) with four circle orifices and a latex microbaloon at its extremity (Marquart C87; Boissy, St-Leger, France). The machine was connected to a polygraph (Narco; Byosystem MMS 200, Houston TX) using the station pull-through method with perfusion of normal saline and the patient lying on the right side. At manometric evaluation, maximum resting pressure (MRP) and maximum squeeze pressure (MSP) were defined as the maximum pressure detected, respectively, on resting and after voluntary contraction. Ultraslow wave activity (USWA) was defined as pressure’s waves with frequency of less than 2/min and an amplitude greater than 25 cm H$_2$O [5].

Data collected on healthy subjects by our anorectal pathophysiological laboratory showed [6] that the normal values of MRP and MSP were, respectively, 68.1 ± 12.3 mmHg mmHg and 112 ± 36.2 mmHg; USWA was detected in the 10% of patients. In accordance to Jones et al. [7], normal range of MRP was 45–85 mmHg; so that CAAF with hypertonic IAS were defined as those with MRP values > 85 mmHg. Manometric follow-up was performed at 12 and 60 months after the surgery.

All patients underwent fissurectomy and anoplasty with V–Y skin flap advancement lying in a gynecological position under spinal or general anesthesia. To expose the anal canal we used four Kocher pliers placed at 3, 6, 9 and 12 h to avoid employing anal retractors; an Eisenhammer retractor or a speculum have been gently introduced just in case of necessity.

After injection of 5 ml of local anesthetic solution (100 mg hydrochloride mepivacaine an 0.025 mf l-adrenaline), the fibrotic edges were excised with a scalpel until normal non-fibrotic anodermal tissue showed sufficient bleeding. The sentinel skin tag and hypertrophied papilla at the level of dentate line were excised when present according to Gupta and Kalaskar [8]. The tissue at the base of the fissure was curetted until there were clean muscle fibers of the IAS. There was no use of diathermy and careful attention was payed to avoiding damages of the IAS. Standard advancement anoplasty was performed using a flap of healthy skin tissue which was mobilized and then advanced with its blood supply to fill in the defect. The flap was secured without tension to the anal canal and the skin was closed tension free in a V–Y manner with interrupted rapid absorbable suture behind the advancement flap. Once the fissurectomy and anoplasty was performed, the botulinum toxin (BT) A (Botox, Allergan, Westport, Ireland) store at −20 °C and diluted in saline to 50 UI/ml was injected into IAS with a 27-gauge needle. Each patient received a total of 30 UI of BT: 15 UI injected at 3 h in gynecological position and 15 UI injected at 9 h. None of the patients assumed concomitant oral medications that could interfere with the action of type A BT (aminoglycosides, baclofen, dantrolene, diazepam) and there was no known hypersensitivity to any component of BT formulation. All procedures were carried out by the same senior surgeon (GDV). Before surgery, all patients received a small volume of phosphate–saline enema. Metronidazole was administered intravenously in a dose of 500 mg 1 h before surgery. Subsequently, it was administered per os at the dosage of 250 mg for 7 days, three times daily.

During the first 2 weeks after the surgery, patients took variable doses of psyllium fibers. A laxative preparation (sennosides) was given orally to subjects who had not yet passed stools 3 days after surgery. Enema, suppositories and all rectal manipulation were avoided. Immediately after surgery, all patients received 100 mg of diclofenac intramuscularly for analgesia and were instructed to take only 100 mg of nimesulide tablets when needed. The primary goal of the study was the patient’s complete healing and the evaluation of incontinence and recurrence rate; the secondary goal included the evaluation of MRP, MSP, USWA, symptom relief (bleeding, itching and pain) and recording pro forma of the immediate and long time complications related to flap surgery.
(anal stenosis, keyhole deformity, urinary retention, related side effects of BT). A complete healing was defined as a complete epithelialization of the advancement skin flap. Both duration and intensity of pain post-defecation were evaluated. Pain intensity was scored with a visual analogical scale (VAS) from 0 to 10, where 0 corresponded to no pain and 10 to the worst pain conceivable. Anal incontinence was assessed pre-operatively and after 1, 3, 6, 12 and 60 months from surgery using the Pescatori grading system [9]: A incontinence for flatus and mucus; B for liquid stool; C for solid stool; 1 for occasional; 2 for weekly and 3 for daily. Patients were discharged 24 h after surgery, afterwards they were examined until they were completely healed and they were also followed up at 1, 12 and 60 months following the surgical procedure. Independently of the scheduled appointments, patients were seen on request.

**Statistical analysis**

Continuous variables were expressed as a mean with standard deviation and qualitative data as absolute frequencies.

**Table 1** Characteristics of Chronic Anal fissure

| Symptoms | No. | Per cent |
|----------|-----|----------|
| Hypertrophied anal papilla | 36  | 80       |
| Skin tags | 30  | 66.6     |
| Pain      | 45  | 100      |
| Bleeding  | 34  | 75.5     |
| Pruritus  | 22  | 48.8     |
| Duration of Symptoms Months (mean ± standard deviation) | 20.1 ± 15.2 |

**Results**

This study includes 15 women and 30 men. At the time of surgical procedure, the median age of the patient was 39 years (range 18–72). Bowel function was normal in 13 patients, 26 patients suffered from constipation and 6 from diarrhea; bowel function was assessed according to the updated Rome diagnostic criteria. Seven women were nulliparous, 4 gave natural birth and all of them underwent an episiotomy and 4 patients gave birth throughout a caesarean section. Clinical features of AF are reported in Table 1.

**Healing fissure and relief of symptoms**

We achieved complete wound healing, in all patients, within 40 days after surgery. Intensity and duration of post-defecation pain was significantly reduced with respect to the pre-operative values starting from the first defecation (P < 0.001) (Fig. 1). None of the patients complained about pain, bleeding or itching 40 days after surgery. Analgesics consumption decreased significantly after first defecation.

**Incontinence**

We recorded 3 cases of pre-operative anal incontinence (6.6%), 2 cases were type A1 and one was type A2 according to Pescatori grading system. In 2 of these patients, anal incontinence resulted worsened at 1 month follow-up after

MRP values were also given as median and range. Student’s *t* test with Welch correction was used to analyze the differences of pain score and pain duration at each registration point. Values of *P* < 0.05 were considered statistically significant.
surgery, while at 3 month follow-up, the grading score was similar than the pre-operative recorded one, Table 2. We observed only 3 “de novo” anal incontinence cases but in all of them the alteration was minor and temporary, Table 3.

### Recurrences

We reported only 3 cases of recurrences, 2 women and 1 man, the site of the recurrences was always different from the primary location. All of them occurred within 2 years from surgery and all were characterized by the persistence of IAS hypertonia. All patients underwent a medical treatment consisting in implementation of fibers in the diet, employ of local products containing nifedipine or lidocaine and anal dilators. All patients responded to the conservative treatment with a complete healing.

### Manometry findings

Pre-operative values of MRP were significantly higher as compared with healthy subjects \((101 \pm 15 \text{ mmHg}; P=0.001)\), whereas MSP values were only slightly increased \((125 \pm 16.8 \text{ mmHg}; P=\text{n.s.})\).

At 12 months and 60 months after surgery MSP values did not significantly differ as compared both with pre-operative levels and healthy control subjects.

At 12 month follow-up, MRP values were significantly lower as compared with pre-operative values \((P<0.001)\). As compared with healthy controls, MRP values had still increased \((P<0.01)\). At 60 months, MRP values were similar compared with healthy control subjects \((P=\text{n.s.})\).

Pre-operative, the presence of USWA was detected in 11 of 45 \((24.4\%)\). A comparison among healthy subjects and patients with CAPF showed a significant difference \((P<0.001)\).

At 12 month follow-up, the detected rate of USWA was lower in comparison to pre-operative values \((P<0.05)\) but they were not significantly higher as compared with healthy subjects. At 60 month follow-up the USWA values of CAPF patient were not statistically significantly different form the ones of healthy subjects.

### Complications and follow-up

There were no cases of urinary retention, anal stenosis or keyhole deformity. No necrosis of the transposed flap was observed. We did not report any local complications related to the injection of the BT. The only complications recorded post-operatively were of slight entity and in no case required further surgery; in particular, 3 infections were detected in the donor site and a partial break down of the flap occurred in one case.

### Discussion

The results of our study show that fissurectomy and ano-plasty associated with the injection of BT, as treatment for patients affected by CAPF with IAS hypertonia, allows an immediate resolution of clinical symptoms as well as a fast healing of the wounds. We recorded a low rate of recurrence \((6.7\%)\); we observed only 3 “de novo” case of post-operative anal incontinence, which were temporary and of slight entity; patients who were already suffering experienced a temporary worsening. Moreover, MRP values started significantly reducing from 12 months \([10]\) after the procedure to reach, at 60 months after surgery, values which were similar to healthy subjects.

Fissurectomy is the most common surgical procedure used to preserve structural and functional integrity of the IAS. It consists in the in the excision of the CAF and it can be associated with the removal of the hypertrophied anal papilla and skin tags. Fissurectomy, as a wound debridement, removes the bradytrophic scar tissue and produces fresh wound edges, creating an acute fissure. Fissure excision without interfering with the IAS was first reported by

| Table 2 | Evaluation of pre-operative anal incontinence cases according to Pescatori grading system from 1 month to 60 months after the surgical procedure |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Pre-operative Anal incontinence cases | 1 month after the procedure | 3 months after the procedure | 6 months after the procedure | 12 months after the procedure | 60 months after the procedure |
| A2 | A2 | A2 | A2 | A2 | A1 |
| A1 | A2 | A1 | A1 | A1 | A1 |
| A1 | A2 | A1 | – | – | A1 |

| Table 3 | Evaluation of post-operative “de novo” anal incontinence cases according to Pescatori grading system from 1 to 60 months after the surgical procedure |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Post-operative “de novo” Anal incontinence cases | 1 month after the procedure | 3 months after the procedure | 6 months after the procedure | 12 months after the procedure | 60 months after the procedure |
| 1 | A1 | – | – | – | – |
| 2 | A1 | A1 | – | – | – |
| 3 | A2 | A1 | – | – | – |
Ashton in 1854, it was recognized to be an effective therapy for CAF, but it was abandoned due to its complications, such as keyhole deformity, which can lead to fecal incontinence [11]. Nevertheless, it has been recently reconsidered as a valid treatment for CAF both in children and adults [12]. This latter surgical procedure has been associated with pharmacological sphincterotomy to improve its results, as well as reduce its complications [15–20]. After surgical fissurectomy, with or without association with chemical sphincterotomy [13, 15, 21–26], we observe a complete second intention wound healing, even after 10 weeks and the rate of failure can reach the 34% [24]. The rate of recurrence reaches up to the 37% in some series [22]. The high rate of recurrence and healing failure of fissurectomy might be related to the fact that this surgical procedure leaves a naked ischemic area, whose previous blood supply arrives from some branches of rectal inferior arteries, which cross the hypertonic IAS fibers [27–29]; in this regard the employ of drugs enabling to reduce the IAS tone aims to improve the blood supply of the naked area.

The employ of a skin graft after fissurectomy was first described by Ruiz-Moreno in 1968. The use a flap to cover up for the naked area after fissurectomy is designed to relocate on this area healthy and fresh blood supplied tissue, perfused by other arterial districts. Another possible advantage of using a flap might be represented by the enlarging effect on the cutaneous circumference of the anal canal, which reduces the risk of splitting.

Several surgical techniques for the use of flaps have been described, we number among them the employ of skin or mucous flaps, skin ones are most frequently hired. Various type of skin flaps are known, such as sliding skin grafts, house advancement flap, V–Y advancement anoplasty, island advancement flap and rotation flaps [31–35].

Surgical procedures that involve the employment of flap guarantee shorter healing period and lower incidence of non-healed wound or recurrence and a minimal interference with the anal continence than the ones observed after surgical fissurectomy itself with or without association with pharmacological sphincterotomy [14, 30, 36, 37]. Fissurectomy associated with anoplasty is a surgical procedure employed for both patients with hypertonic IAS and normotonic IAS [35, 38]. Under the light of the brilliant results of this surgical procedure, some authors suggest using fissurectomy with anal advancement flap as the first line therapy for CAF [30, 39–41].

At the best of our knowledge, the association of fissurectomy with anoplasty and pharmacological sphincterotomy has been cited in one of our series [38, 42] and subsequently in a study published by Halahakoon et al. [43].

In this study, we associated the injection of BT in the IAS to the fissurectomy and anoplasty with V–Y skin advancement flap, to temporarily reduce the IAS pressure [44]. BT A prevents release of acetylcholine at the presynaptic nerve endings and blocks the neuromuscular transmission, thus causing a chemical enervation of the sphincter muscles. Nevertheless, this procedure is not free of risks, most frequently observed complications are peri-anal thrombosis, infections and anal incontinence. In this regard, we noticed that patients affected by pre-operative anal incontinence, experienced an immediate post-operative worsening of the alteration, which diminished to pre-operative level straight after 6 months; even for the 3 “de novo” cases, that we observed in the study, anal incontinence has been temporary and of slight entity but related to the BT action. The only surgical related complications we were able to record were of slight entity and they never required further surgery. Moreover, we recorded 3 cases of recurrence, which have not occurred at the same site as the original lesion and all healed with medical therapy; this might be because of the durability of the advancement flap [30].

However, during the fissurectomy with or without advancement flap, some steps may compromise the integrity of IAS. Therefore, it is mandatory to perform it with a scalpel to avoid excision or cauterization of the IAS fibers. It’s also useful not to use anal retractors, unless necessary and used for a brief period of time. In their prospective randomized clinical Zimmermann et al. [45] showed that trans anal advancement flap for high trans sphincteric fistula results in a significant reduction of MRP values and increase of anal incontinence rate after use of Park retractor when compared with the use of Scott retractor. Van Tets et al. [46] conducted a study in patients who underwent closed hemorrhoidectomy and showed that the reduction of MRP values was greater when a Park retractor was used; they also suggested that overstretching of anal sphincter by a Parks retractor may lead to small nerve branches rupture and consequently to the denervation of IAS fibers. As a matter of fact, in animal studies [47], it has been shown that prolonged stretching may cause local necrosis of external anal sphincter fibers. In view of these latter findings in our study we reached a good exposure of the anal canal just using 4 Kocher pliers placed at 3, 6, 9 and 12 h in gynecological position or just rarely using an anal retractor.

Conclusion

At 5 years after the surgical procedure we achieved good results and observed that post-operative manometric findings were similar to those of healthy subjects; these evidences show us the surgical section of the IAS is not at all necessary for the healing process of the CAPF.

In conclusion, further randomized trials comparing fissurectomy alone versus fissurectomy associated with graft and drugs enabling the reduction of IAS tone are needed to
better define their role in the treatment of CAPF with IAS hypertonia.

Acknowledgements Open access funding provided by Università degli Studi di Palermo within the CRUI-CARE Agreement. All authors contributed to the study. D’Orazio B. and Di Vita G. conceived, devised and designed the manuscript. Geraci G., and Corbo G. collected the case and iconography. D’Orazio B. and Geraci G. wrote the manuscript and participated in the sequence alignment. Di Vita G., Geraci G., Sciumé C. and Martorana G. revised and approved the final manuscript and its conclusions. No further acknowledgement are needed.

Funding No financial support has been obtained in the preparation of this study.

Availability of data The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Compliance with ethical standards

Conflict of interest The Authors report no conflict of interest in this work. The Authors declare that they have no competing interests. This article has not been presented nor published elsewhere, and no financial support has been obtained in its preparation.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent Informed written consent was obtained from all individuals participants included in this study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made.

Bibliography

1. Patti R, Famà F, Barrera T, Migliore G, Di Vita G (2010) Fissurectomy and anal advancement flap for anterior chronic anal fissure without hypertonia of the internal anal sphincter in females. Colorectal Dis 12:1127–1130
2. Garg P, Garg M, Menon GR (2013) Long-term continence disturbance after lateral internal sphincterotomy for chronic anal fissure: a systematic review and meta-analysis. Colorectal Dis 15:e104–117
3. Griffin N, Acheson AG, Tung P, Sheard C, Glazebrook C, Schofield JH (2004) Quality of life in patients with chronic anal fissure. Colorectal Dis 6:39–44
4. Sobrado Júnior CW, Hora JAB, Sobrado LF, Guzela VR, Nahas SC, Cecconello I (2019) Anoplasty with skin tag flap for the treatment of chronic anal fissure. Rev Col Bras Cir. 46:e20192181
5. Patti R, Famà F, Tornambè A, Restivo M, Di Vita G (2010) Early results of fissurectomy and advancement flap for resistant chronic anal fissure without hypertonia of the internal anal sphincter. Am Surg 76:206–210
6. Patti R, Almasio PL, Arcara M, Sparacello M, Termine S, Bonventre S, Di Vita G (2007) Long-term manometric study of anal sphincter function after hemorrhoidectomy. Int J Colorectal Dis. 22:253–257
7. Jones OM, Ramalingam T, Lindsey I, Cunningham C, George BD, Mortensen NJ (2005) Digital rectal examination of sphincter pressures in chronic anal fissure is unreliable. Dis Colon Rectum. 48:349–352
8. Gupta PJ, Kalaskar S (2003) Removal of hypertrophied anal papillae and fibrous anal polyps increases patient satisfaction after anal fissure surgery. Tech Coloproctol. 7:155–158
9. Pescatori M, Anastasio G, Bottini C, Mentasti A (1992) New grading and scoring for anal incontinence. Evaluation of 335 patients. Dis Colon Rectum 35:482–487
10. Patti R, Territo V, Aiello P, Angelo GL, Di Vita G (2012) Manometric evaluation of internal anal sphincter after fissurectomy and anoplasty for chronic anal fissure: a prospective study. Am Surg 78:523–527
11. Ayantunde AA, Debrah SA (2006) Current concepts in anal fissures. World J Surg 30:2246–2460
12. Aigner F, Conrad F (2008) Fissurectomy for treatment of chronic anal fissures. Dis Colon Rectum 51:1163
13. Zeitoun JD, Blanchard P, Fahathallah N, Benfrendj P, Lemarchand N, de Parades V (2018) Long-term outcome of a fissurectomy: a prospective single-arm study of 50 operations out of 349 initial patients. Ann Coloproctol 34:83–87
14. Hancke E, Suchan K, Völker K (2020) Anokutaner Advance-Flap zur sphinkterchonenden chirurgischen Therapie der chronischen Anal fissur. Coloproctologie. 42:270–276
15. Sileri P, Stolfi VM, Franceschilli L, Grande M, Di Giorgio A, D’Ugo S, Attina’ G, D’Eletto M, Gaspari AL (2010) Conservative and surgical treatment of chronic anal fissure: prospective longer term results. J Gastrointest Surg 14:773–780
16. Witte ME, Klaase JM, Koop R (2010) Fissurectomy combined with botulinum toxin A injection for medically resistant chronic anal fissures. Colorectal Dis. 12:e163–169
17. Baraza W, Boereboom C, Shorthouse A, Brown S (2008) The long-term efficacy of fissurectomy and botulinum toxin injection for chronic anal fissure in females. Dis Colon Rectum 51:239–243
18. Scholz T, Hetzer FH, Dindo D, Demartines N, Clavien PA, Hahnloser D (2007) Long-term follow-up after combined fissurectomy and Botox injection for chronic anal fissures. Int J Colorectal Dis 22:1077–1081
19. Arthur JD, Makin CA, El-Sayed TY, Walsh CJ (2008) A pilot comparative study of fissurectomy/diltiazem and fissurectomy/botulinum toxin in the treatment of chronic anal fissure. Tech Coloproctol 12:331–336
20. Engel AF, Eijsbouts QA, Balk AG (2002) Fissurectomy and isosorbide dinitrate for chronic fissure in ano not responding to conservative treatment. Br J Surg 89:79–83
21. Farouk R (2014) Sphincter-preserving therapy for treating a chronic anal fissure: long-term results. J Gastrointest Surg 18:132–134
22. Andicoechea Agorría A, Del Casar Lizcano JM, Barbón Remís E, Jara Quezada JH, Fernández Fernández JC, Sánchez Sánchez MDR, Quintela Baizán I, Vivoso Piñero F (2019) Treatment of a chronic anal fissure with a botulinum toxin A injection and fissurectomy. Rev Esp Enferm Dig 111:672–676
23. Schornagel IL, Witvliet M, Engel AF (2012) Five-year results of fissurectomy for chronic anal fissure: low recurrence rate and minimal effect on continence. Colorectal Dis 14:997–1000
24. Barnes TG, Zafrani Z, Abdelrazeq AS (2010) Fissurectomy combined with high-dose botulinum toxin is a safe and effective treatment for chronic anal fissure and a promising alternative to surgical sphincterotomy. Dis Colon Rectum 58:967–973
25. Lindsey I, Cunningham C, Jones OM, Francis C, Mortensen NJ (2004) Fissurectomy-botulinum toxin: a novel sphincter-sparing procedure for medically resistant chronic anal fissure. Dis Colon Rectum 47:1947–1952
26. Sahebally SM, Walsh SR, Mahmood W, Ahern TM, Joyce MR (2018) Anal advancement flap versus lateral internal sphincterotomy for chronic anal fissure - a systematic review and meta-analysis. Int J Surg. 49:16–21
27. Lund JN, Binch C, McGrath J, Sparrow RA, Scholefield JH (1999) Topographical distribution of blood supply to the anal canal. Br J Surg 86:496–498
28. Klosterhalfen B, Vogel P, Rixen H, Mittermayer C (1989) Topography of the inferior rectal artery: a possible cause of chronic, primary anal fissure. Dis Colon Rectum 32:43–52
29. Schouten WR, Briel JW, Auwerda JJ (1994) Relationship between anal pressure and anodermal blood flow: The vascular pathogenesis of anal fissures. Dis Colon Rectum 37:664–669
30. Giordano P, Gravante G, Grondona P, Ruggiero B, Porrett T, Luniss PJ (2009) Simple cutaneous advancement flap anoplasty for resistant chronic anal fissure: a prospective study. World J Surg 33:1058–1063
31. Samson RB, Stewart WR (1970) Sliding skin grafts in the treatment of anal fissures. Dis Colon Rectum 13:372–375
32. Owen HA, Edwards DP, Khosraviani K, Phillips RK (2006) The house advancement anoplasty for treatment of anal disorders. J R Army Med Corps 152:87–88
33. Kenefick NJ, Gee AS, Durdey P (2002) Treatment of resistant anal fissure with advancement anoplasty. Colorectal Dis 4:463–466
34. Nyam DC, Wilson RG, Stewart KJ, Farouk R, Bartolo DC (1995) Island advancement flaps in the management of anal fissures. Br J Surg 82:326–328
35. Singh M, Sharma A, Gardiner A, Duthie GS (2005) Early results of a rotational flap to treat chronic anal fissures. Int J Colorectal Dis 20:339–342
36. Patel SD, Oxenham T, Praveen BV (2011) Medium-term results of anal advancement flap compared with lateral sphincterotomy for the treatment of anal fissure. Int J Colorectal Dis 26:1211–1214
37. Abramowitz L, Bouchard D, Souffran M, Devulder F, Ganansia R, Castinel A, Suduca JM, Soudan D, Varastet M, Staumont G (2013) Sphincter-sparing anal-fissure surgery: a 1-year prospective, observational, multicentre study of fissurectomy with anoplasty. Colorectal Dis 15:359–367
38. Patti R, Fami F, Tornambè A, Asaro G, Di Vita G (2010) Fissurectomy combined with anoplasty and injection of botulinum toxin in treatment of anterior chronic anal fissure with hyperotnia of internal anal sphincter: a pilot study. Tech Coloproctol 14:31–36
39. Chambers W, Sajal R, Dixon A (2010) V-Y advancement flap as first-line treatment for all chronic anal fissures. Int J Colorectal Dis 25:645–648
40. Hancke E, Rikas E, Suchan K, Völke K (2010) Dermal flap coverage for chronic anal fissure: lower incidence of anal incontinence compared to lateral internal sphincterotomy after long-term follow-up. Dis Colon Rectum 53:1563–1568
41. Marti L, Post S, Herold A, Schwander O, Hetzer F, Strütmatter B, Iesalnieks I, Huth M, Schmit-Lauber M, Weyandt G, Ommert A, Ebinger SM (2020) S3-Leitlinie analfissur. AWMF-Registernummer: 081-010. Coloproctology 42:90–196
42. Patti R, Guercio G, Territo V, Aiello P, Angelo GL, Di Vita G (2012) Advancement flap in the management of chronic anal fissure: a prospective study. Updates Surg 64:101–106
43. Halahakoov VC, Pitt JP (2014) Anal advancement flap and botulinum toxin (A) for chronic anal fissure (CAF). Int J Colorectal Dis 29:1175–1177
44. Brisinda G, Cadeddu F, Brandara F, Marriga G, Vanella S, Nigro C, Maria G (2008) Botulinum toxin for recurrent anal fissure following lateral internal sphincterotomy. Br J Surg 95:774–778
45. Zimmerman DD, Gosselink MP, Hop WC, Darby M, Briel JW, Schouten WR (2003) Impact of two different types of anal retractor on fecal continence after fistula repair: a prospective, randomized, clinical trial. Dis Colon Rectum 46:1674–1679
46. van Tets WF, Kuipers JH, Tran K, Mollen R, van Goor H (1997) Influence of Parks’ anal retractor on anal sphincter pressures. Dis Colon Rectum 40:1042–1045
47. Li L, Zhang JZ, Lu GW, He GR, Lui XH (1996) Damaging effects of anal stretching on the external anal sphincter. Dis Colon Rectum 39:1249–1254

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.